| Literature DB >> 28177895 |
Fang Su1, Jun Zhao2, Shukui Qin3, Rui Wang1, Yumei Li1, Qiang Wang4, Yi Tan5, Hao Jin5, Fangquan Zhu5, Yurong Ou6, Zenong Cheng6, Wen Su1, Fuyou Zhao1, Yan Yang1, Zhengguang Zhou1, Jiyue Zheng1, Yawei Li1, Zhongwen Li7, Qiong Wu1.
Abstract
Hepatocellular carcinoma (HCC) is a common malignancy found worldwide and is associated with a high incidence of metastasis and vascular invasion. Elucidating the molecular mechanisms that underlie HCC tumorigenesis and progression is necessary for the development of novel therapeutics. By analyzing the Cancer Genome Atlas Network (TCGA) dataset, we identified Thrombospondin 4 (THBS4) is significantly overexpressed in HCC samples and is correlated with prognosis. Overexpression of THBS4 was also highly correlated with vascular invasion of advanced HCC. While THBS4 is often overexpressed in HCC it has also been shown to inhibit tumor growth by mediating cell-to-cell and cell-to-matrix interactions. Here, we identified that knockdown of THBS4 inhibits migration and invasion of HCC cells and inhibits HCC induced angiogenesis. MiRNAs are crucial regulators of multiple cellular processes, and aberrant expression of miRNAs has been observed to effect cancer development and progression. We further found that miR-142 is an upstream regulator of THBS4 in HCC cells. Moreover, miR-142 was significantly down-regulated in HCC tissue samples and correlated with overexpression of THBS4. Overexpression of miR-142 inhibited invasion and angiogenesis of HCC cells and re-expression of THBS4 overcame these effects of miR-142 expression. Stable over-expression of miR-142 significantly inhibited tumour growth in a xenograft tumour model through inhibiting THBS4 expression and tumor angiogenesis. In conclusion, our findings indicate that loss of miR-142 results in the over-expression of THBS4, which enhances HCC migration and vascular invasion. Thus, targeting THBS4 or miR-142 may provide a promising therapeutic strategy for treatment of advanced HCC.Entities:
Keywords: THBS4; hepatocellular carcinoma; miR-142; migration; vascular invasion
Mesh:
Substances:
Year: 2017 PMID: 28177895 PMCID: PMC5410303 DOI: 10.18632/oncotarget.15054
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1THBS4 is overexpressed in HCC and associated with vascular invasion and survival
A. Relative expression level of THBS4 in HCC tumor and non-tumor samples in TCGA dataset. B. Relative expression of THBS4 in 30 pairs of HCC and adjacent normal tissue by RT-qPCR analysis (T: tumor, AN: adjacent normal). C. Relative expression of THBS4 in 30 pairs of HCC samples with vascular invasion (VI) and non-vascular invasion (NI). D. Representative images of THBS4 in HCC tumors with vascular invasion (VI-T) and non-vascular invasion (NI-T) and adjacent normal tissues (AN). E. Association of THBS4 expression with patient survival. F. Expression of THBS4 in TCGA dataset.
Figure 2Knockdown of THBS4 inhibits migration and invasion of HCC cells
A. Representative images of cell migration using wound healing assay. B. Representative images of transwell assays measuring in vitro Matrigel cell invasion, following depletion of THBS4 in HCC cells. C. Quantification of invasion assay. The invading cells were quantified by plotted as average plotting them as the average number of cells per field of view from 3 different independent experiments as described.
Figure 3Knockdown of THBS4 inhibits HCC cells induced angiogenesis
A. Representative tube formation by endothelial cells after incubation with conditioned media (CM) from HuH7 and Hep3B cells transfected with siScrmble or siTHBS4 using the tube formation assay. B. Quantification of the number of branches in each group. C. Representative images of endothelial cell migration after incubation with conditioned media (CM) from HuH7 and Hep3B cells transfected with siScramble or siTHBS4 using the endothelial recruitment assay. D. Quantification of the numbers of migrating endothelial cells in each group.
Figure 4miR-142 is an upstream regulator of THBS4 in HCC cells
A. Putative microRNAs targeting THBS4 as predicted by TargetScan. B. The prediction and correlation heat map in different dataset by miRGator 3.0. C. Relative expression of miR-142 in 30 pairs of HCC and adjacent normal samples by RT-qPCR analysis (T: tumor, AN: adjacent normal). D. Inverse correlation of THBS4 and miR-142 in a group of HCC samples based on the RT-qPCR analysis. E. HuH7 cells co-transfected with P-miR-142 with wild-type (wt) or mutant (mut) pGL3-THBS4 constructs followed by luciferase reporter assays. Data were normalized by the ratio of Firefly and Renilla luciferase activities measured at 48 h post-transfection. The bar graph shows the mean ±SD in three independent transfection experiments. *P<0.05. F. Western blotting analysis of THBS4 expression in P-miR-control and P-miR-142-transfected HuH7 cells.
Figure 5Overexpression of miR-142 inhibits invasion and angiogenesis of HCC cells
A. Representative images of transwell in vitro Matrigel cell invasion following overexpression of miR-142 in HCC cells. B. Quantification of invading cells plotted as the average number of cells per field of view from 3 independent experiments as described. C. Representative tube formation by endothelial cells after incubation with conditioned media (CM) from HuH7 and Hep3B cells transfected with p-miR-control or p-miR-142 using the tube formation assay. D. Quantification of the number of branches in each group.
Figure 6miR-142 inhibits tumor formation of HCC cells through targeting THBS4
A. Western blot of re-expression of THBS4 in stable transfected HuH7-p-miR-142 cells. B. Representative images of transwell in vitro Matrigel cell invasion in HuH7-p-miR-142 cells expressing THBS4. C. Representative tube formation by endothelial cells after incubation with conditioned media (CM) from HuH7-p-miR-142 cells transfected with pLenti-control or pLenti-THBS4 using the tube formation assay. D. Tumor growth of xenografts of HuH7-p-miR-control and HuH7-p- miR-142. E and F. IHC staining of THBS4 and the angiogenesis marker CD31 in tumour tissues from HuH7-p-miR-control and HuH7-p-miR-142 tumor tissues.